| Report ID | 277251 |
| Drug Identification Number | 02258595 |
| Brand name | HUMIRA |
| Common or Proper name | adalimumab |
| Company Name | ABBVIE CORPORATION |
| Market Status | MARKETED |
| Active Ingredient(s) | ADALIMUMAB |
| Strength(s) | 40MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | Pre-filled syringe and PEN |
| ATC code | L04AB |
| ATC description | IMMUNOSUPPRESSANTS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2026-05-29 |
| Actual discontinuation date | |
| Remaining supply date | |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 8401 TRANS-CANADA HIGHWAY SAINT-LAURENT, QUEBEC CANADA H4S 1Z1 |
| Company contact information | Should you require any additional information, please contact our Customer Service Department at 1-888-704-8270. |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2026-02-04 | French | Compare |
| v1 | 2026-02-04 | English | Compare |
Showing 1 to 2 of 2